Edition:
United States

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

25.05USD
17 Nov 2017
Change (% chg)

$0.02 (+0.08%)
Prev Close
$25.03
Open
$24.93
Day's High
$25.60
Day's Low
$24.37
Volume
208,060
Avg. Vol
326,757
52-wk High
$29.20
52-wk Low
$13.13

Select another date:

Tue, Nov 7 2017

BRIEF-Editas Medicine announces Q3 loss per share $0.64

* Editas Medicine announces third quarter 2017 results and update

BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101

* Editas Medicine receives EMA's orphan medicinal product designation for EDIT-101 for the treatment of LCA10

BRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10

* Editas Medicine Inc - announced that company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10)

BRIEF-Editas Medicine Q2 loss per share $0.65

* Editas Medicine announces second quarter 2017 results and update

BRIEF-Editas Medicine achieves milestone under Juno Therapeutics collaboration

* Editas Medicine achieves milestone under Juno Therapeutics collaboration for technical progress towards overcoming the tumor microenvironment Source text for Eikon: Further company coverage:

BRIEF-Editas Medicine names Andrew Hirsch to board of directors

* Hirsch will also serve as chairman of audit committee of board, hirsch is currently chief financial officer of agios pharmaceuticals Source text for Eikon: Further company coverage:

Select another date: